

# PIMSH16 Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk Antineoplastic Agents

In this lesson, you will learn the required documentation for the **MIPS PIMSH# 16 Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center** quality measure.

**First receipt of high or moderate emetic risk intravenous antineoplastic agent during cycle 1 day 1 of first therapy where:**

- Numerator Criteria 1: Patients are administered prior to treatment a four-drug combination of a neurokinin 1 (NK1) receptor antagonist, a serotonin (5-HT3) receptor antagonist, dexamethasone, and olanzapine
- Numerator Criteria 2: Patients are administered prior to treatment a two-drug combination of a 5-HT3 receptor antagonist, and dexamethasone.

For the purposes of this measure, the following antiemetics would meet the measure:


- Antiemetics administered on the same day as cycle 1 day 1 of the therapy **OR**
- Any new or refill prescription order of antiemetics on the same day as cycle 1 day 1 of the therapy or within 89 days prior to cycle 1 day 1 of the therapy **OR**
- Any record of antiemetics as active on the medication list within 90 days prior to cycle 1 day 1 of the therapy

The screenshot shows the 'Regimens (0)' tab selected in the top navigation bar. Below the navigation bar, the 'Regimen Search' section is visible. A dropdown menu for 'Diagnosis/Problem' is open, showing 'Lymphoma, Hodgkins (C81.C)'. A red box highlights the 'SEARCH FOR REGIMENS' button. Below the search button, the 'Additional Data' section is visible, containing text about Stage IIIB-Pathology, Disease Status, Classification, and Lymphatic Site. Red circles with numbers 1, 2, and 3 point to the 'Regimens (0)' tab, the dropdown menu, and the 'SEARCH FOR REGIMENS' button respectively.

1. In the Orders tab, go to the Regimens tab.
2. Select the diagnosis/problem from the drop-down list.
3. Click **SEARCH FOR REGIMENS**.

**iKnowMed<sup>SM</sup> Generation 2**

Clear Value Plus - Pathway Decision Support



**Quincy Hart (69 / M)**

MRN: 98765  
DOB: 12/07/1953  
Insurance:

Clear Value Plus <sup>SM</sup>

Regimen Type: Show Definitions

- Chemotherapy
- Immunotherapy
- Targeted therapy
- Hormone
- Supportive care
- Other

**4**

CANCEL

**4. Select Regimen Type.**

Quincy Hart (69 / M)

Line of Therapy: Show Definitions

- 1st Line or Induction
- 2nd Line
- 3rd Line
- 4th Line
- 5th Line
- 6th Line
- Beyond 6th Line
- Stem cell transplant
- Maintenance

**5**

CANCEL

**5. Respond to therapy and staging inquiries in Clear Value Plus.**

## iKnowMed<sup>SM</sup> Generation 2

SHOW	Clinical Trials At This Practice (2)			Febrile Neutropenic Risk	Emetogenic Risk	Action
HIDE	Treatment Options (13)	P&T Preferred	NCCN COE	Febrile Neutropenic Risk	Emetogenic Risk	Action
	Brentuximab vedotin + Bendamustine D1,2 Q21D		2A	intermediate (10-20%)	moderate-high (80-90%)	SELECT
	Brentuximab vedotin + Nivolumab Q21D		2A	low (<10%)	low (10-29%)	SELECT
	Brentuximab vedotin D1,8 + Ifosfamide CIV D2 + Carboplatin D2 + Etoposide D1-3 (ICE) Q21D		2A	high (>20%)	high (>90%)	SELECT
	Brentuximab vedotin Q21D		2A	low (<10%)	low (10-29%)	SELECT
	DHAP (Cisplatin) Q21D		2A	high (>20%)	high (>90%)	SELECT
	Gemcitabine + Oxaliplatin (GemOx) Q14D (Hodgkins, NHL)		2A	intermediate (10-20%)	moderate-high (80-90%)	SELECT
	Gemcitabine D1,8 + Dexamethasone D1-4 + Cisplatin (GDP) Q21D		2A	low (<10%)	high (>90%)	SELECT
	GVD		2A	low	low	SHOW OPTIONS
	ICE		2A	high	high	SHOW OPTIONS
	Nivolumab		2A	low	low	SHOW OPTIONS

6. The emetogenic risk level is shown for each regimen.
7. Select the desired regimen by clicking on **SELECT**.

Regimen Name \* (as it will appear on the flowsheet)

DHAP (Cisplatin) Q21D

Cycle \*

21

Starting On \*

1

Start Date

06/01/2023

Patient Height / Weight

(06/01/2023): 182.88 CM / 88.45 KG

BSA (DuBois And DuBois)

2.11 m2

Associated Problem \*

Lymphoma, Hodgki

Line of Therapy \*

4th Line

Stage

IIIB

Treatment Intent

Palliative

Regimen Comments

Instructions to Ordering Provider

Clear Value Plus Decision Details

Decision recorded by ZZAlexander, Sharon on 06/01/2023

Value Pathway

View Decision Details

✓ NCCN Guideline

Emetic potential: Emetic Risk: High (>90%)

FN potential: Febrile Neutropenia (FN) Risk: High (>20%)

References

Patient Education

DHAP

Estimated Infusion time

3 hours, 0 minutes

Requires Financial Approval

Ordered from Location\*

Central Region-Boulder Clin

Perform Location

Unspecified-to be completed by Scheduler

Specified

Type

Select

Location

Search Locations

OK

9

8. Review and complete any missing data in the Patient Regimen Details box.
9. Click OK.

iKnowMed<sup>SM</sup> Generation 2

DHAP (Cisplatin) Q21D		
CHEMOTHERAPY	Add an Order	Search Orderables
<input type="checkbox"/> <b>Dexamethasone IV</b> Dexamethasone IV 40 mg intravenously once. <b>Instructions:</b> Dexamethasone may be given IV or PO.		Dose 40 mg
<input checked="" type="checkbox"/> <b>Dexamethasone Oral</b> Dexamethasone Oral 1 mg tablet 1 tablet orally daily. <b>Dispense:</b> 30 Tablet <b>Refills:</b> 1 <b>Duration:</b> 30 days <b>Allow Substitution</b>		Dose 1 mg
CHEMOTHERAPY CIV	Add an Order	Search Orderables
<input checked="" type="checkbox"/> <b>Cisplatin IV</b> 211 mg (100 mg/m <sup>2</sup> ; BSA: 2.11 m <sup>2</sup> = 211 mg) Cisplatin IV 211 mg via continuous infusion. <b>Admin over:</b> 24 hours <b>Instructions:</b> TOTAL CYCLE DOSE = 100 mg/m <sup>2</sup> CIV over 24 hours on Day 1. Patient to be seen for a pump disconnect on Day 2. Refer to drug stability guidelines.		Dose 100 mg/m <sup>2</sup>
CHEMOTHERAPY DOSE 1 OF 2	Add an Order	Search Orderables

10. The selected regimen of DHAP includes Cisplatin, a high risk emetogenic drug.

To meet the measure numerator, patients receiving a high to moderate risk emetogenic drug are administered **either a four-drug combination of a neurokinin 1 (NK1) receptor antagonist, a serotonin (5-HT3) receptor antagonist, dexamethasone, and olanzapine or a two-drug combination of a 5-HT3 receptor antagonist and dexamethasone prior to treatment.**



Review the orders to ensure the appropriate premedications have been included.

New Orders (0)	Medications (0)	Regimens (46)	Order Review	Order History	Drafts
<b>Order Review</b>   SIGN ORDERS   SAVE AS DRAFT   CANCEL   VIEW BY ORDER TYPE   VIEW BY ORDER DATE   <input type="checkbox"/> Print orders on save					
for 2 doses (start at end of cisplatin infusion). Doses less than 1 gram infuse over 30 minutes. Doses greater than or equal to 1 gram use preservative free diluent.					
<b>ADDITIONAL MEDICATIONS</b>					
<b>Pegfilgrastim Subcutaneous (via wearable injector)</b> (C1D2,C2D2,C3D2,C4D2,C5D2,C6D2) Pegfilgrastim Subcutaneous (via wearable injector) 6 mg/0.6 mL syringe, w/ wearable injector 6 mg subcutaneously using wearable injector once. <b>Instructions:</b> May be applied by a healthcare professional on the same day a day regimen using only the co-packaged pegfilgrastim. Within 3 minutes of filling the On-body reservoir, the device must be applied to the abdomen, the back of arm should only be used if there is a caregiver available to monitor the injector. Pegfilgrastim will begin pegfilgrastim over 45 minutes. <b>NOTE:</b> This is Neulasta On Body Injector.					
<b>PREMEDICATIONS</b>					
<input checked="" type="checkbox"/> <b>Palonosetron IV</b> (C1D1,C2D1,C3D1,C4D1,C5D1,C6D1) Palonosetron IV 0.25 mg intravenously Push once.					
<input checked="" type="checkbox"/> <b>Fosaprepitant IV</b> (C1D1,C2D1,C3D1,C4D1,C5D1,C6D1) Fosaprepitant IV 150 mg intravenously Piggyback once.					
<input checked="" type="checkbox"/> <b>Olanzapine Oral</b> (C1D1,C2D1,C3D1,C4D1,C5D1,C6D1) Olanzapine Oral 2.5 mg tablet 2.5 mg orally every day at bedtime. Take for 4 days starting Day 1 of chemotherapy for nausea. Dispense: 16 Tablet Refills: 0 Allow Substitution					

iKnowMed<sup>SM</sup> Generation 2

New Orders (0) Medications (0) Regimens (46) **Order Review** Order History

**Order Review** SIGN ORDERS SAVE AS DRAFT CANCEL VIEW BY ORDER TYPE VIEW BY ORDER DATE

Associated problem(s): Prostate Cancer \* (C61); Lymphoma, Hodgkins (C81.01)

06/01/2023

**DHAP (Cisplatin) Q21D**

**CHEMOTHERAPY**

**Dexamethasone Oral** (C1D1,C2D1,C3D1,C4D1,C5D1,C6D1)

**Rx** Dexamethasone Oral 1 mg tablet  
1 tablet orally daily. Dispense: 30 Tablet Refills: 1 Duration: 30 days Allow Substitution

**CHEMOTHERAPY CIV**

11. Click SIGN ORDERS.

Chart Summary Clinical Profile **Flowsheet** Ord

**Flowsheet** Find: Find a result or order

6/01/23 (Thu)

◀ DHAP (Cisplatin) Q21D ▶ **C1D1 Insurance**

◀ CHEMOTHERAPY ▶

◀ Dexamethasone Oral ▶ **Rx 1 mg qday**

◀ CHEMOTHERAPY CIV ▶

◀ Cisplatin IV ▶ **ins. 211 mg (100 mg/m...**

◀ CHEMOTHERAPY DOSE 1 OF 2 ▶

◀ Cytarabine IV ▶ **in**

◀ CHEMOTHERAPY DOSE 2 OF 2 ▶

◀ Cytarabine IV ▶ **in**

◀ ADDITIONAL MEDICATIONS ▶

◀ Pegfilgrastim Subcutaneous (via wearabl... ▶ **in**

◀ PREMEDITATIONS ▶

◀ Palonosetron IV ▶ **ins. 0.25 mg**

◀ Fosaprepitant IV ▶ **ins. 150 mg**

◀ Olanzapine Oral ▶ **Rx 2.5 mg qhs**

◀ \*\*PRN\*\* HYPERSENSITIVITY MEDS ▶



The ordered premedications can now be seen on the Flowsheet.

This concludes the lesson for the required documentation for the **MIPS PIMSH# 16 Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center** quality measure.